Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity

https://doi.org/10.1016/j.diabres.2010.11.003Get rights and content

Abstract

Objective

The aim of this study was to evaluate the association of serum visfatin, adiponectin and leptin with 2 diabetes mellitus (T2DM) in the context of the role of obesity or insulin resistance, which is not well understood.

Methods

A total of 76 newly-diagnosed T2DM patients and 76 healthy control subjects, matched for age, body mass index (BMI) and sex ratio, were enrolled. Anthropometric parameters, glycemic and lipid profile, insulin resistance (measured by homeostasis model assessment of insulin resistance index [HOMA-IR]), leptin, adiponectin, and visfatin were assessed.

Results

On the contrary to adiponectin, serum leptin and visfatin levels were higher in T2DM patients compared with controls (10.07 ± 4.5, 15.87 ± 16.4, and 5.49 ± 2.4 vs. 12.22 ± 4.9 μg/ml, 8.5 ± 7.8 ng/ml and 3.58 ± 2.2 ng/ml, respectively, P < 0.01). Waist circumference and BMI were correlated with leptin and adiponectin but not with visfatin. Leptin, adiponectin and visfatin all were associated with T2DM following adjusting for obesity measures. After controlling for HOMA-IR, visfatin remained as an independent predictor of T2DM (odds ratio = 1.32, P < 0.05). In a multiple regression analysis to determine visfatin only triglycerides and fasting glucose remained in the model (P < 0.05).

Conclusion

Elevation of visfatin in T2DM is independent of obesity and insulin resistance and is mainly determined by fasting glucose and triglycerides.

Introduction

Excess obesity is regarded as the most important risk factor for type 2 diabetes mellitus [1]. Visceral adipose tissue seems to have more insidious effects than subcutaneous fat [2], [3] and removal of visceral fat results in improvement of insulin sensitivity [4], [5]. Adipose tissue, particularly visceral fat is, nowadays, considered as an active metabolic organ releasing different adipocytokines including leptin, adiponectin and visfatin [6], [7].

Adiponectin, the most profusely expressed adipocytokine, is inversely associated with obesity [7], [8], and is suggested to have insulin sensitizing, anti-hypertensive, and anti-inflammatory effects [9], [10], [11]. It is generally supposed that adiponectin prevents endothelial dysfunction and the development of atherosclerosis by acting as an anti-inflammatory, antioxidant and vasodilator agent [12].

By contrast, leptin is directly related to obesity [13]. Leptin resistance reflected by hyperleptinemia is suggested to link obesity to hypertension, impaired glucose metabolism and pro-atherogenic status [14]. In this respect, leptin signaling is responsible for modulation of food intake and energy expenditure [13], [14]. Leptin to adiponectin ratio is regarded as a potent atherogenic index and an excellent predictor of insulin resistance in diabetic patients [15], [16].

An initial study showed that visfatin, as an adipocytokine, has insulin-mimetic effects including inhibition of hepatic glucose release, augmentation of glucose uptake in adipocytes and myocytes and increase in triglyceride synthesis and its accumulation in pre-adipocytes [17]. However, since the results of this study were not confirmed by subsequent analyses, it was in part retracted [18]. In addition, visfatin is identified as a pre-B cell colony stimulating factor [19]. It has been shown that circulating visfatin is more strongly correlated with visceral fat compared to subcutaneous fat [17], [20]. Weight loss reduces elevated visfatin levels in morbidly obese subjects [21].

Although due to aforementioned findings obesity, adipocytokines and type 2 diabetes are strongly interrelated, the mechanism by which obesity leads to insulin resistance is obscure and the role of adipocytokines in this pathologic process remains to be fully determined. Particularly, the association between serum visfatin and diabetes in the context of the role of obesity or insulin resistance in establishment of diabetes is not well understood. It would be an interesting topic to evaluate the association between diabetes mellitus and different adipocytokines when the potent affect of body adiposity and insulin resistance in establishment of diabetes is restrained, in a well-balanced study. In this study, we aimed to evaluate and compare the associations of adiponectin, leptin and visfatin with diabetes mellitus and use different adjustment models to evaluate the independent association between diabetes and these adipocytokines.

Section snippets

Participants

Seventy six newly diagnosed diabetic patients who were referred to Vali-Asr hospital, a general hospital affiliated to Tehran University of Medical Sciences, were enrolled in this study. The control group was comprised of healthy subjects, who were regularly visited at our general clinic of the same hospital, and were individually matched with diabetic patients in age, body mass index (BMI) and sex ratio. Subjects with underlying disease (e.g. cancer, glumerolonephritis, inflammatory or

Results

Principal characteristics of diabetic and non-diabetic participants are presented in Table 1. There was no significant difference between diabetic and non-diabetic participants regarding mean age (50.1 ± 9.6 vs. 50.6 ± 7.9 years), BMI (28.7 ± 4.1 vs. 27.7 ± 3.3 kg/m2) and male to female ratio (40/36 vs. 42/34). Diabetic subjects had higher visfatin and leptin levels and lower adiponectin level compared to non-diabetic subjects (P < 0.01).

Anthropometric measures (i.e. BMI and waist circumference) were

Discussion

Diabetic subjects had higher levels of leptin and visfatin and lower levels of adiponectin compared to non-diabetic participants. The correlation coefficients of leptin and adiponectin with obesity measures reached significant levels. Regression analysis revealed that all adipocytokines are associated with diabetes status and this association remains after adjustment for BMI and waist circumference. However, after adjustment for HOMA-IR, only visfatin was independently associated with diabetes.

Conflict of interests

There are no conflicts of interest.

References (44)

  • S. Klein et al.

    Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease

    N Engl J Med

    (2004)
  • A. Thorne et al.

    A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding

    Int J Obes Relat Metab Disord

    (2002)
  • N.E. Gulcelik et al.

    Role of adipocytokines in predicting the development of diabetes and its late complications

    Endocrine

    (2009)
  • Y. Okamoto et al.

    Adiponectin: a key adipocytokine in metabolic syndrome

    Clin Sci (Lond)

    (2006)
  • K. Hotta et al.

    Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients

    Arterioscler Thromb Vasc Biol

    (2000)
  • W.S. Chow et al.

    Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study

    Hypertension

    (2007)
  • H. Tilg et al.

    Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases

    Clin Sci (Lond)

    (2008)
  • C. Antoniades et al.

    Adiponectin: from obesity to cardiovascular disease

    Obes Rev

    (2009)
  • P.J. Havel

    Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance

    Proc Nutr Soc

    (2000)
  • M.L. Correia et al.

    Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome

    Diabetes Obes Metab

    (2006)
  • N. Satoh et al.

    Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients

    Diabetes Care

    (2004)
  • A. Fukuhara et al.

    Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

    Science

    (2005)
  • Cited by (51)

    • An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients

      2016, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
      Citation Excerpt :

      Visfatin (also known as nicotinamide phosphorybosil transferase) is an adipocytokine, which widely expressed in liver, skeletal muscles, bone marrow and predominantly secreted by white VAT [9]. Recently, elevated level of vistafin was found in overweight/obesity, T2DM, metabolic syndrome and CV disease [10,11]. Circulating level of vistafin has revealed closely relation rather VAT mass and low-grade systemic inflammation then insulin resistance [12,13].

    View all citing articles on Scopus
    View full text